139 related articles for article (PubMed ID: 15155541)
1. Acute and long-term effects of nateglinide on insulin secretory pathways.
Ball AJ; Flatt PR; McClenaghan NH
Br J Pharmacol; 2004 May; 142(2):367-73. PubMed ID: 15155541
[TBL] [Abstract][Full Text] [Related]
2. Alterations of insulin secretion following long-term manipulation of ATP-sensitive potassium channels by diazoxide and nateglinide.
Ball AJ; Flatt PR; McClenaghan NH
Biochem Pharmacol; 2005 Jan; 69(1):59-63. PubMed ID: 15588714
[TBL] [Abstract][Full Text] [Related]
3. Induced desensitization of the insulinotropic effects of antidiabetic drugs, BTS 67 582 and tolbutamide.
McClenaghan NH; Ball AJ; Flatt PR
Br J Pharmacol; 2000 May; 130(2):478-84. PubMed ID: 10807689
[TBL] [Abstract][Full Text] [Related]
4. Actions of glucagon-like peptide-1 on KATP channel-dependent and -independent effects of glucose, sulphonylureas and nateglinide.
McClenaghan NH; Flatt PR; Ball AJ
J Endocrinol; 2006 Sep; 190(3):889-96. PubMed ID: 17003289
[TBL] [Abstract][Full Text] [Related]
5. Drug-induced desensitization of insulinotropic actions of sulfonylureas.
Ball AJ; McCluskey JT; Flatt PR; McClenaghan NH
Biochem Biophys Res Commun; 2000 Apr; 271(1):234-9. PubMed ID: 10777708
[TBL] [Abstract][Full Text] [Related]
6. Nateglinide and mitiglinide, but not sulfonylureas, induce insulin secretion through a mechanism mediated by calcium release from endoplasmic reticulum.
Shigeto M; Katsura M; Matsuda M; Ohkuma S; Kaku K
J Pharmacol Exp Ther; 2007 Jul; 322(1):1-7. PubMed ID: 17409272
[TBL] [Abstract][Full Text] [Related]
7. Interaction of nateglinide with K(ATP) channel in beta-cells underlies its unique insulinotropic action.
Hu S
Eur J Pharmacol; 2002 May; 442(1-2):163-71. PubMed ID: 12020694
[TBL] [Abstract][Full Text] [Related]
8. Glucose-dependent and glucose-sensitizing insulinotropic effect of nateglinide: comparison to sulfonylureas and repaglinide.
Hu S; Wang S; Dunning BE
Int J Exp Diabetes Res; 2001; 2(1):63-72. PubMed ID: 12369728
[TBL] [Abstract][Full Text] [Related]
9. Nateglinide, a non-sulfonylurea rapid insulin secretagogue, increases pancreatic islet blood flow in rats.
Iwase M; Nakamura U; Uchizono Y; Nohara S; Sasaki N; Sonoki K; Iida M
Eur J Pharmacol; 2005 Aug; 518(2-3):243-50. PubMed ID: 16023099
[TBL] [Abstract][Full Text] [Related]
10. Specific desensitization of sulfonylurea- but not imidazoline-induced insulin release after prolonged tolbutamide exposure.
McClenaghan NH; Ball AJ; Flatt PR
Biochem Pharmacol; 2001 Mar; 61(5):527-36. PubMed ID: 11239495
[TBL] [Abstract][Full Text] [Related]
11. Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation.
McKillop AM; Duffy NA; Lindsay JR; Green BD; Patterson S; O'Harte FP; Bell PM; Flatt PR
Eur J Endocrinol; 2009 Dec; 161(6):877-85. PubMed ID: 19755410
[TBL] [Abstract][Full Text] [Related]
12. Effects of nateglinide on the secretion of glycated insulin and glucose tolerance in type 2 diabetes.
Lindsay JR; McKillop AM; Mooney MH; O'Harte FP; Flatt PR; Bell PM
Diabetes Res Clin Pract; 2003 Sep; 61(3):167-73. PubMed ID: 12965106
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent.
McLeod JF
Clin Pharmacokinet; 2004; 43(2):97-120. PubMed ID: 14748619
[TBL] [Abstract][Full Text] [Related]
14. Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166).
Ikenoue T; Akiyoshi M; Fujitani S; Okazaki K; Kondo N; Maki T
Br J Pharmacol; 1997 Jan; 120(1):137-45. PubMed ID: 9117089
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic restoration of the early insulin response in pre-diabetic monkeys controls mealtime glucose excursions without peripheral hyperinsulinaemia.
Dunning BE; Deacon R; Gutierrez C; Paladini S; Valentin MA; Foley JE
Diabetologia; 2003 Mar; 46 Suppl 1():M22-9. PubMed ID: 12652355
[TBL] [Abstract][Full Text] [Related]
16. Effect of the administration of a single dose of nateglinide on insulin secretion at two different concentrations of glucose in healthy individuals.
González-Ortiz M; Hernández-Salazar E; Martínez-Abundis E
J Diabetes Complications; 2005; 19(6):356-60. PubMed ID: 16260353
[TBL] [Abstract][Full Text] [Related]
17. Long-term effects of glibenclamide and nateglinide upon pancreatic islet function in normal and diabetic rats.
Laghmich A; Ladrière L; Malaisse-Lagae F; Malaisse WJ
Pharmacol Res; 1999 Dec; 40(6):475-82. PubMed ID: 10660944
[TBL] [Abstract][Full Text] [Related]
18. Stimulation of insulin secretion in clonal BRIN-BD11 cells by the imidazoline derivatives KU14r and RX801080.
Ball AJ; Flatt PR; McClenaghan NH
Pharmacol Res; 2000 Dec; 42(6):575-9. PubMed ID: 11058411
[TBL] [Abstract][Full Text] [Related]
19. Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus.
Kahn SE; Montgomery B; Howell W; Ligueros-Saylan M; Hsu CH; Devineni D; McLeod JF; Horowitz A; Foley JE
J Clin Endocrinol Metab; 2001 Dec; 86(12):5824-9. PubMed ID: 11739446
[TBL] [Abstract][Full Text] [Related]
20. Desensitization of sulphonylurea- and nutrient-induced insulin secretion following prolonged treatment with glibenclamide.
Ball AJ; Flatt PR; McClenaghan NH
Eur J Pharmacol; 2000 Nov; 408(3):327-33. PubMed ID: 11090651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
